According to The Insight Partners' research, the South & Central America Regenerative Medicines Market was valued at US$ 413.5 Million in 2024 and is expected to reach US$ 1,434.7 Million by 2031, registering a CAGR of 19.6% from 2025 to 2031.
Integration of Artificial Intelligence in regenerative medicine and introduction of advanced regenerative therapies are among the critical factors attributed to drive the South & Central America regenerative medicines market growth.
Integrating artificial intelligence (AI) into regenerative medicine enhances drug discovery, improves personalized therapies, and accelerates development timelines. AI-driven technologies facilitate handling complex biological data and optimizing manufacturing processes, leading to more efficient regenerative therapies. Aspen Neuroscience's ANPD-001, currently in Phase II clinical trials for Parkinson's disease, exemplifies a pioneering AI-enabled regenerative therapy. This therapy utilizes AI and machine learning (ML) to reprogram patient skin cells into dopamine-producing neurons. Proprietary AI-based genomic tests ensure cell quality, resulting in safer, more personalized treatments. This approach demonstrates how AI validation can enhance the precision and biological safety of regenerative medicine products while reducing the risk of rejection.
Several startups illustrate this trend further. The Argentinian company MesencHyal-T employs AI-powered cellular therapies aimed at bone regeneration. It uses machine learning in its scalable production processes to standardize stem cell expansion and improve the osteogenic potential of the cells. Additionally, it collaborates with hospitals and research centers to facilitate quicker clinical deployment, showing how AI aids in discovery as well as real-world applications and outcome predictions. Similarly, the UK-based company Trogenix integrates genomics, bioinformatics, and machine learning into its synthetic super-enhancer viral immunotherapy for precise gene control and targeted regenerative treatments in cancer and age-related tissue repair.
AI-driven platforms contribute to product launches that accelerate drug candidate generation. Insilico Medicine, a leader in AI drug discovery, achieved a milestone with INS018_055, a small-molecule drug candidate for idiopathic pulmonary fibrosis. This drug is the first entirely AI-discovered and AI-designed medication to enter Phase II trials. Insilico's collaboration with pharmaceutical giant Sanofi, a US$1.2 billion deal, leverages Insilico's AI platform to identify novel targets and predict clinical outcomes, highlighting the ecosystem of partnerships centered around AI-driven regenerative solutions.
In manufacturing and therapy design, companies such as US-based Shinobi Therapeutics utilize AI-enabled platforms to develop immune-evasive induced pluripotent stem cell (iPSC) therapies, featuring genetic edits that evade immune detection. This strategy offers off-the-shelf regenerative treatments suitable for oncology, diabetes, and autoimmune disorders, showcasing how AI simplifies the complex genetic engineering required for advanced regenerative products.
AI helps overcome challenges in regenerative medicine, such as high developmental costs and lengthy timelines. It enhances predictive modeling, quality control, and scaling up production. AI algorithms analyze vast datasets to predict patient-specific responses to stem cell therapies, aiding in creating personalized treatment plans and improving clinical outcomes. Industry forecasts for 2025 suggest that AI adoption will increase dramatically, becoming foundational in personalizing regenerative protocols worldwide.
The integration of AI in regenerative medicine represents a groundbreaking trend. AI streamlines therapy development and enhances personalization, quality, and clinical effectiveness. This approach positions regenerative medicine for unprecedented growth and patient impact in the coming years, underscoring the convergence of cutting-edge technology with biological innovation to revolutionize the design, testing, and delivery of regenerative therapies.
The integration of AI in regenerative medicine represents a groundbreaking trend. AI streamlines therapy development and enhances personalization, quality, and clinical effectiveness. This approach positions regenerative medicine for unprecedented growth and patient impact in the coming years, underscoring the convergence of cutting-edge technology with biological innovation to revolutionize the design, testing, and delivery of regenerative therapies.
On the contrary, the high-cost barriers in regeneration treatment hamper the growth of the South & Central America regenerative medicines market.
South & Central America Regenerative Medicines Market Segmentation Analysis:
- By Product Type, the South & Central America Regenerative Medicines Market is segmented into Cell Based Products, Gene Therapy, and Tissue Engineering. The Tissue Engineering segment is projected to expand at 19.5% CAGR during 2025 - 2031.
- By Cell Based Products - Products Type, the South & Central America Regenerative Medicines Market is segmented into Stem Cell and Cell Based Immuno Therapy. The Stem Cell segment is projected to expand at 19.4% CAGR during 2025 - 2031.
- By Application, the South & Central America Regenerative Medicines Market is segmented into Oncology, Neurological Disorders, Wound Healing and Skin Regeneration, Ophthalmology, Orthopedics and Musculoskeletal, Immunology, Genetic Disorders, and Others. The Oncology segment is projected to expand at 20.1% CAGR during 2025 - 2031.
By country, the South & Central America Regenerative Medicines Market is categorized into Brazil, Argentina, and the Rest of South & Central America. Brazil is projected to expand at 20.0% CAGR during 2025 - 2031.
Key players operating in the Regenerative Medicines Market are Novartis AG, Bristol-Myers Squibb Co, Johnson & Johnson, Takeda Pharmaceutical Co Ltd, BioMarin Pharmaceutical Inc., JCR Pharmaceuticals Co. Ltd., Daiichi Sankyo Co Ltd, Vertex Pharmaceuticals Inc, CSL Behring LLC, Bluebird Bio Inc, Ferring Pharmaceuticals, and Japan Tissue Engineering Co., Ltd., among others.
- In June 2025, BioMarin Pharmaceutical Inc. announced new data underscoring the long-term efficacy and safety of ROCTAVIAN (valoctocogene roxaparvovec-rvox) were presented at the 33rd Congress of the International Society on Thrombosis and Haemostasis (ISTH).
- In September 2024, Johnson & Johnson announced long-term results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI (ciltacabtagene autoleucel) significantly extended overall survival (OS) in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor (PI), reducing the risk of death by 45 percent versus standard therapies of pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd).
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com